Literature DB >> 24805800

Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes.

Anan S Jarab1, Reham Almrayat, Salam Alqudah, Ekbal Thehairat, Tareq L Mukattash, Maher Khdour, Sharrel Pinto.   

Abstract

BACKGROUND: The prevalence of diabetes in Jordan is among the highest in the world, making it a particularly alarming health problem there. It has been indicated that poor adherence to the prescribed therapy lead to poor glycemic control and enhance the development of diabetes complications and unnecessary hospitalization.
OBJECTIVE: To explore factors associated with medication nonadherence in patients with type 2 diabetes in Jordan. Findings would help guide the development of future pharmaceutical care interventions for patients with type 2 diabetes.
SETTING: This study was conducted in an outpatient diabetes clinic at the Royal Medical Services Hospital.
METHOD: Variables including sociodemographics, disease and therapy factors, diabetes knowledge, health-related quality of life in addition to adherence assessment were collected for 171 patients with type 2 diabetes using medical records, custom-designed and validated questionnaires. Logistic regression was performed to develop a model with variables that best predicted medication non-adherence in patients with type 2 diabetes in Jordan. MAIN OUTCOME MEASURE: Variables which significantly and independently associated with medication nonadherence in patients with type 2 diabetes in Jordan.
RESULTS: Patients were found four times less likely to adhere to their medications with each unit increase in the number of prescribed medications (OR = 0.244, CI = 0.08-0.63) and nine times less likely to adhere to their medications if they received more than once daily dosing of diabetic medication (OR = 0.111, CI = 0.04-2.01). Patients in the present study were also approximately three times less likely (OR = 0.362, CI = 0.24-0.87) and twice less likely (OR = 0.537, CI = 0.07-1.31) to adhere to their medications if they reported having concerns about side effects and if they were taking metformin therapy respectively. Finally, participants were found twice more likely to adhere to medications if they had one or more Microvascular complication (OR = 0.493, CI = 0.08-1.16).
CONCLUSION: Simplifying dosage regimen, selecting treatments with lower side effects along with an emphasis on diabetes complications should be taken into account in future interventions designed to improve health outcomes for patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805800     DOI: 10.1007/s11096-014-9938-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  36 in total

1.  Overcoming the hurdles to achieving glycemic control.

Authors:  Kenneth M Shaw
Journal:  Metabolism       Date:  2006-05       Impact factor: 8.694

2.  Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong.

Authors:  Vivian W Y Lee; Pak Yip Leung
Journal:  Am J Health Syst Pharm       Date:  2003-12-15       Impact factor: 2.637

Review 3.  Adherence in diabetes: can we define it and can we measure it?

Authors:  W L McNabb
Journal:  Diabetes Care       Date:  1997-02       Impact factor: 19.112

4.  Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.

Authors:  Anan Sadeq Jarab; Salam Ghazi Alqudah; Tareq Lewis Mukattash; Ghassan Shattat; Tariq Al-Qirim
Journal:  J Manag Care Pharm       Date:  2012-09

5.  A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic.

Authors:  Brian K Irons; Ranee J Lenz; Stephanie L Anderson; Benita L Wharton; Butch Habeger; H Glenn Anderson
Journal:  Pharmacotherapy       Date:  2002-10       Impact factor: 4.705

6.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

7.  Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan.

Authors:  Hiroyuki Sakamaki; Shunya Ikeda; Naoki Ikegami; Yasuko Uchigata; Yasuhiko Iwamoto; Hideki Origasa; Toshiki Otani; Yoichi Otani
Journal:  Value Health       Date:  2006 Jan-Feb       Impact factor: 5.725

8.  Factors associated with poor glycemic control among patients with type 2 diabetes.

Authors:  Maysaa Khattab; Yousef S Khader; Abdelkarim Al-Khawaldeh; Kamel Ajlouni
Journal:  J Diabetes Complications       Date:  2009-03-17       Impact factor: 2.852

9.  Medication adherence and associated hemoglobin A1c in type 2 diabetes.

Authors:  Kimberley Krapek; Kathleen King; Susan S Warren; Karen G George; Dorothy A Caputo; Karen Mihelich; Elizabeth M Holst; Michael B Nichol; Sheng G Shi; Kevin B Livengood; Steve Walden; Teresa J Lubowski
Journal:  Ann Pharmacother       Date:  2004-07-06       Impact factor: 3.154

10.  An increase in prevalence of diabetes mellitus in Jordan over 10 years.

Authors:  Kamel Ajlouni; Yousef S Khader; Anwar Batieha; Haitham Ajlouni; Mohammed El-Khateeb
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

View more
  12 in total

1.  Exploring variables associated with medication non-adherence in patients with type 2 diabetes mellitus.

Authors:  Walid Al-Qerem; Anan S Jarab; Mohammad Badinjki; Dana Hyassat; Raghda Qarqaz
Journal:  PLoS One       Date:  2021-08-23       Impact factor: 3.240

Review 2.  Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR.

Authors:  Catherine M Kuecker; Eva M Vivian
Journal:  Diabetes Metab Syndr Obes       Date:  2016-02-23       Impact factor: 3.168

Review 3.  Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations.

Authors:  Paolo Girardi; Roberto Brugnoli; Giovanni Manfredi; Gabriele Sani
Journal:  Drugs R D       Date:  2016-12

4.  Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Authors:  Takashi Kadowaki; Nobuya Inagaki; Hirotaka Watada; Kazuyo Sasaki; Kazumi Mori-Anai; Tomohisa Iwasaki; Tatsuki Teranishi
Journal:  Adv Ther       Date:  2022-02-09       Impact factor: 3.845

Review 5.  Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination.

Authors:  Joshua W Fleming; Laurie W Fleming; Courtney S Davis
Journal:  Diabetes Metab Syndr Obes       Date:  2015-06-25       Impact factor: 3.168

6.  Adherence and treatment satisfaction in liver transplant recipients.

Authors:  Abdulkareem M Albekairy; Abdulmalik M Alkatheri; Anan Jarab; Nabil Khalidi; Khalifah Althiab; Abdulrahman Alshaya; Khalid Bin Saleh; Wesam W Ismail; Amjad M Qandil
Journal:  Saudi J Gastroenterol       Date:  2016 Mar-Apr       Impact factor: 2.485

7.  A focus group study of patient's perspective and experiences of type 2 diabetes and its management in Jordan.

Authors:  Anan S Jarab; Tareq L Mukattash; Ahmad Al-Azayzih; Maher Khdour
Journal:  Saudi Pharm J       Date:  2018-01-31       Impact factor: 4.330

Review 8.  Individual factors increasing complexity of drug treatment-a narrative review.

Authors:  Steffen J Schmidt; Viktoria S Wurmbach; Anette Lampert; Simone Bernard; Walter E Haefeli; Hanna M Seidling; Petra A Thürmann
Journal:  Eur J Clin Pharmacol       Date:  2020-04-01       Impact factor: 2.953

9.  Factors Associated with Medication Non-Adherence in Patients with Dyslipidemia.

Authors:  Eman Alefishat; Anan S Jarab; Walid Al-Qerem; Lina Abu-Zaytoun
Journal:  Healthcare (Basel)       Date:  2021-06-28

Review 10.  Exploring of Determinants Factors of Anti-Diabetic Medication Adherence in Several Regions of Asia - A Systematic Review.

Authors:  Much Ilham Novalisa Aji Wibowo; Nanang Munif Yasin; Susi Ari Kristina; Yayi Suryo Prabandari
Journal:  Patient Prefer Adherence       Date:  2022-01-27       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.